Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.70 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | PAM | P19021 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107851 | 1.00 | HTR2A (0.70) | HTR2AIDO1PAMGRIK1GRIK2 | |
| SCHEMBL107852 | 1.00 | HTR2A (0.70) | HTR2AIDO1PAMGRIK1GRIK2 | |
| Styrene SCHEMBL812462 | 0.90 | HTR2A (0.59) | HTR2AIDO1PAMGRIK1GRIK2 | |
| SCHEMBL14037582 | 0.86 | HTR2A (0.70) | HTR2AIDO1PAMGRIK1GRIK2 | |
| SCHEMBL7647009 | 0.86 | HTR2A (0.54) | HTR2AIDO1GRIK1GRIK2SIGMAR1 | |
| SCHEMBL7145801 | 0.85 | MAOB (0.56) | HTR2AIDO1PAMMAOB | |
| SCHEMBL28785261 | 0.83 | HTR2A (0.51) | HTR2ASIGMAR1 | |
| SCHEMBL8826291 | 0.83 | HTR2A (0.66) | HTR2AIDO1PAMGRIK1GRIK2 | |
| SCHEMBL19586953 | 0.83 | HTR2A (1.00) | HTR2AIDO1PAMGRIK1GRIK2 | |
| SCHEMBL19604562 | 0.83 | HTR2A (0.66) | HTR2AIDO1PAMGRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-1970368-B1 | METHOD FOR PRODUCING OLEFIN COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-7985872-B2 | Method for producing olefin compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20090036620-A1 | METHOD FOR PRODUCING OLEFIN COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1970368-A1 | METHOD FOR PRODUCING OLEFIN COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HTR2A 3630/4885IDO1 4758/4885PAM 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.